Luca Durelli

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP.

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

Re: Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther. 2003;25:105-118.

Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.

Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy.

Is multiple sclerosis a disease that requires frequent beta interferon dosing?

Immunodetection of anti-MAG IgM antibody by cross-reactivity to LA-N-1 neuroblastoma cells.

The importance of maintaining effective therapy in multiple sclerosis.

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

Interferon-beta1a for the treatment of multiple sclerosis.

Adherence to interferon-beta treatment and results of therapy switching.

The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.

Risk factors for tumor occurrence in patients with myasthenia gravis.

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose.

Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2.

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.

Epigenetic therapy for Friedreich ataxia.

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.